Core Insights - PennantPark Floating Rate Capital Ltd. reported its financial results for the fourth quarter and fiscal year ended September 30, 2025, highlighting a stable net investment income and a focus on middle-market investments [1][2]. Financial Performance - For the quarter ended September 30, 2025, the company reported net investment income of $27.5 million, or $0.28 per share, compared to $18.0 million, or $0.24 per share, for the same period in 2024 [19][30]. - The total investment income for the year ended September 30, 2025, was $261.4 million, up from $186.4 million in 2024 [17][30]. - The company declared distributions of $0.31 per share for the quarter and $1.23 per share for the year, totaling $30.5 million and $113.9 million, respectively [30]. Portfolio and Investment Activity - As of September 30, 2025, the investment portfolio totaled $2,773.3 million, consisting of $2,513.6 million in first lien secured debt [8][35]. - The weighted average yield on debt investments was 10.2% at quarter-end [2][8]. - The company invested $633.0 million in the quarter and $1,741.3 million for the year, with a focus on middle-market companies [10][12]. Debt and Liquidity - The company had a credit facility of $683.8 million and a regulatory debt-to-equity ratio of 1.66x as of September 30, 2025 [2][26]. - The annualized weighted average cost of debt was 6.8% for the year ended September 30, 2025, down from 8.5% in 2024 [25][26]. - Cash equivalents available for investing were $122.7 million as of September 30, 2025 [26]. Recent Developments - In August 2025, the company formed a joint venture, PennantPark Senior Secured Loan Fund II, LLC, with a commitment of $200 million to invest in middle-market loans [31]. - The company acquired a portfolio of high-quality assets totaling approximately $250 million, projected to enhance Core NII by one to two cents per share quarterly [32]. - Subsequent to the quarter-end, the company sold $118 million of assets to PSSL and $191 million to PSSL II, using the proceeds to reduce its debt-to-equity ratio to 1.41x [33].

Core Insights - Sana Biotechnology, Inc. is set to present at two investor conferences in December, providing a business overview and updates from CEO Steve Harr [1][5] - The presentations will be accessible via webcast on the company's Investor Relations page, with replays available for 30 days post-conference [2] Company Overview - Sana Biotechnology focuses on creating engineered cells as medicines, aiming to repair and control genes, and replace missing or damaged cells [3] - The company operates in Seattle, WA, Cambridge, MA, and South San Francisco, CA, with a vision to make therapies broadly available to patients [3]

Core Insights - PennantPark Investment Corporation reported its financial results for the fourth quarter and fiscal year ended September 30, 2025, highlighting a decrease in net investment income and net asset value per share compared to the previous year [1][19][23]. Financial Performance - For the year ended September 30, 2025, the company had a net investment income of $46.1 million, or $0.71 per share, down from $60.1 million, or $0.92 per share in the previous year, reflecting a decrease of approximately 23% [19][23]. - The net asset value per share decreased to $7.11 from $7.56, representing a decline of 5.9% [2][32]. - Total investment income for the year was $122.4 million, down from $143.8 million in the prior year [16][35]. Portfolio and Investment Activity - As of September 30, 2025, the investment portfolio totaled $1,287.3 million, with 45% in first lien secured debt and 28% in preferred and common equity [2][6]. - The company made purchases of investments totaling $746.6 million for the year, while sales and repayments amounted to $810.4 million [2][8]. - The weighted average yield on debt investments was 11.0% for the year [2][6]. Expenses and Liabilities - Total expenses for the year were $76.3 million, a decrease from $83.7 million in the previous year, primarily due to lower interest expenses [17][19]. - The company had outstanding borrowings of $426.5 million under the Truist Credit Facility as of September 30, 2025, with a weighted average interest rate of 6.5% [25][26]. Distributions - During the year ended September 30, 2025, the company declared total distributions of $62.7 million, or $0.96 per share, compared to $57.4 million, or $0.88 per share in the previous year [29]. Market Position and Strategy - The company maintains a focus on the core middle market, which is characterized by attractive credit spreads and lower leverage, aiming to support net investment income through realizations of equity holdings [5][37].

Core Insights - Brilliant Earth Group, Inc. is a global leader in ethically sourced fine jewelry and will participate in upcoming investor events [1][2][3] Group 1: Upcoming Investor Events - On December 3, 2025, the Company will participate in NobleCon21, hosting a presentation at 1:00pm ET and holding investor meetings throughout the day [2] - On December 11, 2025, the Company will participate in the KeyBanc Capital Markets Consumer Conference virtually, with a fireside chat at 11:15am ET and additional investor meetings [3] Group 2: Company Overview - Brilliant Earth was founded in 2005 with a mission to create a more transparent, sustainable, and compassionate jewelry industry [4] - The Company reported full year Net Sales of $422 million for 2024 and has achieved positive Adjusted EBITDA for 17 consecutive quarters since going public in 2021 [4] - Brilliant Earth operates 42 showrooms across the United States and serves customers in over 50 countries worldwide [4]

Core Points - Lavoro Limited received a notice of non-compliance from Nasdaq due to delayed filing of its Form 20-F for the year ended June 30, 2025 [1][2] - The company is required to submit a plan by November 28, 2025, to regain compliance with Nasdaq's listing rules [3][4] - The delay in filing is attributed to complexities associated with the EJ Plan announced in June 2025 [2] Company Overview - Lavoro is Brazil's largest agricultural inputs retailer and a leading producer of agricultural biological products [5] - The company operates across Latin America, including Brazil, Colombia, Uruguay, and Ecuador, and empowers small and medium-sized farmers with emerging agricultural technologies [5]

ARLINGTON, Va., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three months and full fiscal year ended September 30, 2025. Fiscal Year 2025 Financial Highlights Revenue of $2.3 billion for fiscal year 2025 and $1.0 billion for the fourth quarter, compared to $2.7 billion and $1.2 billion from the same ...

Core Viewpoint - Oxford Industries, Inc. plans to release its third quarter fiscal 2025 financial results on December 10, 2025, after market close, followed by a conference call to discuss the results [1]. Company Information - Oxford Industries is a leader in the apparel industry, owning and marketing several distinctive brands including Tommy Bahama®, Lilly Pulitzer®, Johnny Was®, Southern Tide®, The Beaufort Bonnet Company®, Duck Head®, and Jack Rogers® [3]. - The company's stock has been traded on the New York Stock Exchange since 1964 under the symbol OXM [3]. Conference Call Details - The conference call will be hosted by Thomas C. Chubb III, Chairman, CEO, and President, and K. Scott Grassmyer, Executive Vice President, CFO, and COO, starting at 4:30 p.m. ET [1]. - A live webcast of the conference call will be available on the company's website, with a replay accessible until December 24, 2025 [2].

Core Insights - Rani Therapeutics is participating in the Evercore Healthcare Conference on December 3, 2025, with CEO Talat Imran and CFO Svai Sanford presenting [1] - The company focuses on oral delivery of biologics and drugs, aiming to replace traditional injection methods with its proprietary RaniPill capsule technology [2] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company dedicated to advancing technologies for orally administered biologics and drugs [2] - The RaniPill capsule is a novel, proprietary, and patented platform technology designed to facilitate oral dosing instead of subcutaneous or intravenous methods [2] - The company has successfully conducted multiple preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill capsule technology [2]

Core Insights - ORIC Pharmaceuticals, Inc. is a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance [3] - The company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 11:15 a.m. ET [1] - A webcast of the fireside chat will be available on the company's investor website, with a replay accessible for 90 days post-event [2] Company Overview - ORIC Pharmaceuticals is dedicated to improving patients' lives by overcoming resistance in cancer [3] - The company's clinical stage product candidates include ORIC-944, an allosteric inhibitor targeting the polycomb repressive complex 2 (PRC2) for prostate cancer, and enozertinib (ORIC-114), a brain-penetrant inhibitor for various genetically defined cancers [3] - ORIC has offices located in South San Francisco and San Diego, California [3]

Core Insights - Zoom Communications, Inc. reported a total revenue of $1,229.8 million for the third fiscal quarter, reflecting a year-over-year increase of 4.4% as reported and 4.2% in constant currency [4][5] - The company emphasized its commitment to an AI-first platform, highlighting the growth in adoption of its AI Companion 3.0 and Custom AI Companion, contributing to strong customer experience metrics [2][4] - The financial results indicate significant profitability, with GAAP EPS increasing by 204.5% year-over-year to $2.01, and non-GAAP EPS rising by 10.1% to $1.52 [4][5] Financial Performance - Total revenue for Q3 was $1,229.8 million, with Enterprise revenue at $741.4 million, up 6.1% year-over-year, and Online revenue at $488.4 million, up 2.0% [4][5] - GAAP operating margin stood at 25.2%, while non-GAAP operating margin was 41.2% [5][36] - Operating cash flow reached $629.3 million, marking a 30.2% increase year-over-year, with a cash flow margin of 51.2% and free cash flow margin of 50.0% [4][5][37] Shareholder Returns - The company repurchased approximately 5.1 million shares in Q3, totaling 32.5 million shares repurchased under the current plan [4][9] - The Board of Directors authorized an additional $1.0 billion for stock repurchase, increasing the total authorization to $1.310 billion [9][11] Customer Metrics - The number of customers contributing over $100,000 in trailing 12 months revenue increased by 9.2% year-over-year, totaling 4,363 customers [4][13] - The trailing 12-month net dollar expansion rate for Enterprise customers was reported at 98% [13] - Online average monthly churn remained stable at 2.7% year-over-year, with 74.4% of total Online MRR from customers with a continual term of service of at least 16 months [13] Financial Outlook - For Q4 FY 2026, total revenue is expected to be between $1.230 billion and $1.235 billion, with non-GAAP income from operations projected between $477.0 million and $482.0 million [13] - The full fiscal year 2026 revenue guidance is between $4.852 billion and $4.857 billion, with non-GAAP income from operations expected between $1.955 billion and $1.960 billion [13]